학술논문
Assessing use of inhalable nicotine products within complex markets: the dilemma of heated tobacco products.
Document Type
Editorial & Opinion
Author
Miller CR; Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA connor.miller@roswellpark.org.; Xu SS; Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada.; Smith DM; Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.; Sutanto E; Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.; Goniewicz ML; Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.; Quah ACK; Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada.; Fong GT; Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada.; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Source
Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 9209612 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-3318 (Electronic) Linking ISSN: 09644563 NLM ISO Abbreviation: Tob Control Subsets: MEDLINE
Subject
Language
English
Abstract
The introduction of electronic inhalable products, such as nicotine vaping products (NVPs) and heated tobacco products (HTPs), has further diversified the nicotine market landscape. This poses unique challenges in measuring self-reported nicotine use behaviours, which have been the hallmark of tobacco surveillance systems. This paper raises concerns of potential measurement error for electronic inhalable product use in surveys due to similarities in product design between NVPs and HTPs, as well as changing trends in cannabis administration. We identify several strategies for addressing this issue (eg, including descriptive preambles in surveys that differentiate product classes from one another; incorporating survey questions that probe beyond an initial question regarding product use). In the absence of comprehensive validation studies, caution is warranted when interpreting survey results that rely on self-reported HTP use.
Competing Interests: Competing interests: GTF has served as an expert witness or consultant for governments defending their country’s policies or regulations in litigation. GTF has served as a paid expert consultant to the Ministry of Health of Singapore in reviewing the evidence on plain/standardised packaging. MLG received research grant from Pfizer and served as a member of scientific advisory board to Johnson & Johnson.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Competing Interests: Competing interests: GTF has served as an expert witness or consultant for governments defending their country’s policies or regulations in litigation. GTF has served as a paid expert consultant to the Ministry of Health of Singapore in reviewing the evidence on plain/standardised packaging. MLG received research grant from Pfizer and served as a member of scientific advisory board to Johnson & Johnson.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)